WS23.3 ICM is sensitive to detect potentiation of CFTR-mediated Cl− secretion in patients with cystic fibrosis and the G551D mutation treated with ivacaftor.

Authors :: Graeber, S.Y.
Hug, M.J.
Sommerburg, O.
Mainz, J.G.
Heinzmann, A.
Tümmler, B.
Mall, M.A.
Source :: Journal of Cystic Fibrosis. Jun2014, Vol. 13 Issue S2, pS43-S43. 1p.
Publication Year :: 2014

Subjects :: *CYSTIC fibrosis treatment
*GENETIC mutation
*CYSTIC fibrosis transmembrane conductance regulator
*SECRETION
*LUNG diseases

Full Text Access

Tools